

Living Cell Technologies Limited

ACN: 104 028 042

ASX: LCT

OTCQX: LVCLY

ASX ANNOUNCEMENT

Publication of successful pre-clinical trial of NTCELL[®] for Parkinson's disease.

16 September 2013: Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited today announced the publication of the preclinical trial of their cell therapy NTCELL[®] in a non-human primate model of Parkinson's disease.

The studies have been published in the Journal of Parkinson's Disease and have been made freely available by the company via open access:

<http://iospress.metapress.com/content/e0003031197w8148/fulltext.pdf>

When compared with monkeys implanted with empty capsules or subjected to sham surgery, monkeys treated with an implant of NTCELL into the affected brain area demonstrated significant:

- Recovery from movement abnormalities.
- Improvements in neurological defects.
- Increase in neural connections and number of dopamine-producing neurons in the affected area of the brain.

"The published results show that NTCELL was well tolerated with no evidence of inflammation or other adverse reaction. The improvements were seen within two weeks and lasted for at least six months, the trial endpoint." says Dr Paul Tan, Chief Science and Medical Officer of LCT.

The pre-clinical studies form the scientific basis of the Phase I "first-in-man" clinical trial which is currently underway in New Zealand.

"These exciting preclinical results indicate that NTCELL can protect and regenerate brain tissue which would otherwise be lost, potentially delaying or even preventing the effects of Parkinson's disease." adds Dr Andrea Grant, Managing Director of LCT. "If the product is shown to be safe and effective in humans in our current Phase I and subsequent clinical trials, registration via a fast-tracked development programme could be possible."

In the clinical trial in humans, NTCELL will be transplanted into the affected area of the brain where substantial death of neurons and other cells has occurred. NTCELL is comprised of choroid plexus cells, which are naturally occurring "support" cells for the brain and when transplanted appear to help to protect the brain and repair damaged nerve tissue. LCT's propriety capsule technology, Immupel[®] covers the transplanted cells with a protective coating that protects them from attack by the patient's immune system.

The Phase I clinical trial is an open label investigation of the safety and clinical effect of NTCELL in four people who have been diagnosed with Parkinson's for at least four years. The first patient has been recruited and is expected to be implanted during 2013. The patient will then be monitored for two months to confirm no serious adverse safety events. At that time, the independent data safety monitoring board (DSMB) will consider the safety data and advise if the transplants for the remaining three patients can proceed.

LCT and Otsuka Pharmaceutical Factory are co-developing NTCELL as a treatment for Parkinson's disease. Under the agreement, LCT has already received an A\$3m cash payment and OPF is funding all of the research and development costs associated with the Phase I clinical trial, estimated at A\$2.1m. In addition, LCT will receive a second cash payment of A\$2m provided the DSMB authorise the remaining three implants later in the year.

– Ends –

For further information: www.lctglobal.com

At the company:

Dr Andrea Grant
Managing Director
Tel: +64 9 270 7941
Mobile: +64 21 078 5421
agrant@lctglobal.com

About Parkinson's disease

- Parkinson's disease affects approximately 4 million people worldwide.
- It is a progressive neurological condition which is related to a deficit of dopamine as a result of degeneration of dopamine-producing brain cells
- Most pharmaceutical treatment options focus on restoring the balance of dopamine and other neurotransmitters
- For many patients, drugs become ineffective as the severity of the symptoms increases over time
- More recently, high-frequency deep brain stimulation (DBS) of regions of the brain involved in the control of movement has become a widely practised and accepted form of management for complex Parkinson's disease
- DBS does not impact on disease progression, is not curative or neuroprotective and does not improve major non-motor symptoms such as cognition, poor balance or autonomic dysfunction

About Living Cell Technologies

Living Cell Technologies (LCT) is an Australasian biotechnology company and world leader in developing cell therapies to treat diseases with high unmet clinical need. To date, the company has taken two therapeutic candidates into clinical development: DIABECCELL® for the treatment of Type 1 diabetes and NTCELL®, which is in Phase I clinical trials in New Zealand for the treatment of Parkinson's disease.

Through an innovative joint venture with international pharmaceutical company Otsuka Pharmaceutical Factory (OPF), LCT has secured funding, based on the achievement of clinical milestones, for the clinical development of DIABECCELL and the Phase I clinical trials of NTCELL in

Parkinson's disease. LCT retains a 50% share of future profits from DIABECCELL and NTCELL and a perpetual, exclusive licence to continue to develop products using intellectual property held outside the DOL partnership.

LCT's unique, proprietary technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system, which often have negative side-effects.

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its research and development, operations and manufacturing facilities based in New Zealand.

For more information visit www.lctglobal.com or follow @lctglobal on Twitter

LCT disclaimer

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential", "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.